Sam Brusco, Associate Editor12.13.23
Xpan, a company dedicated to minimally invasive surgical innovation, has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance for its Xpan universal trocar system, as well as successful completion of the first clinical procedures using Xpan in the U.S.
The universal trocar system is a radially expandable access device that first enters the body as a 3mm port, then can be dilated during the procedure at the surgeon’s discretion to 5mm and/or 12mm as required by the surgery’s demands. Xpan said using these minimally invasive instruments and techniques can minimize tissue disruption and morbidity by using radial dilation instead of cutting the tissue when larger instruments are needed in certain situations.
The company estimated over five million abdominal and thoracic procedures in the U.S. alone could benefit from its universal trocar system.
"Our goal is to provide patients and the healthcare system with a product that can reduce complications and provide superior post-operative outcomes,” said Xpan CEO Zaid Atto. “This technology was developed in collaboration with forward thinking surgeons who recognize an opportunity and need for innovation in laparoscopic surgical access.”
The company said it will continue to gather feedback from clinicians to support its value proposition before commercially releasing the technology.
The universal trocar system is a radially expandable access device that first enters the body as a 3mm port, then can be dilated during the procedure at the surgeon’s discretion to 5mm and/or 12mm as required by the surgery’s demands. Xpan said using these minimally invasive instruments and techniques can minimize tissue disruption and morbidity by using radial dilation instead of cutting the tissue when larger instruments are needed in certain situations.
The company estimated over five million abdominal and thoracic procedures in the U.S. alone could benefit from its universal trocar system.
"Our goal is to provide patients and the healthcare system with a product that can reduce complications and provide superior post-operative outcomes,” said Xpan CEO Zaid Atto. “This technology was developed in collaboration with forward thinking surgeons who recognize an opportunity and need for innovation in laparoscopic surgical access.”
The company said it will continue to gather feedback from clinicians to support its value proposition before commercially releasing the technology.